{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:51:22Z","timestamp":1791265882368,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the clinical characteristics of newly diagnosed multiple myeloma (NDMM) patients with 1q21 gain\/amplification (1q21+), construct and validate a progression\u2010free survival (PFS) prediction model, and explore the clinical implications of model\u2010based risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 186 newly diagnosed multiple myeloma patients with 1q21+ treated between 2018 and 2024. Patients were randomly assigned at a 7:3 ratio to a training cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009131) and an internal split\u2010sample validation cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200955). Independent prognostic factors for PFS were identified using multivariate Cox regression to construct a nomogram (the HLBP model). Model performance was evaluated through bootstrap resampling, time\u2010dependent receiver operating characteristic (ROC) curves, calibration plots, and Kaplan\u2013Meier survival analysis. Furthermore, the model's predictive accuracy was compared with conventional staging systems and established prognostic models. Finally, risk\u2010stratified exploratory analyses were conducted to assess treatment\u2010associated outcomes across different risk groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher hemoglobin was protective, whereas elevated lactate dehydrogenase, increased \u03b22\u2010microglobulin, and TP53 deletion were adverse prognostic factors. The HLBP model yielded AUCs of 0.805, 0.885, and 0.847 at 6, 12, and 24\u2009months in the training cohort, and 0.747, 0.827, and 0.712 in the internal split\u2010sample validation cohort. Patients stratified into high\u2010 and low\u2010risk groups showed significantly different PFS outcomes. Risk\u2010stratified analyses suggested heterogeneous prognostic patterns associated with induction treatment regimens and autologous stem cell transplantation across risk groups. Overall, the HLBP model demonstrated superior predictive performance compared with existing staging systems and previously reported prognostic models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The HLBP model showed promising preliminary performance for predicting PFS in patients with 1q21+ NDMM and may provide an exploratory framework for individualized risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72077","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:15:09Z","timestamp":1788678909000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and Validation of a Progression\u2010Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain\/Amplification"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9585-0292","authenticated-orcid":false,"given":"Yuexuan","family":"Rao","sequence":"first","affiliation":[{"name":"Department of Hematology Affiliated Hospital of Xuzhou Medical University  Xuzhou Jiangsu Province China"},{"name":"The First Clinical College of Xuzhou Medical University  Xuzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyou","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology Affiliated Hospital of Xuzhou Medical University  Xuzhou Jiangsu Province China"},{"name":"The First Clinical College of Xuzhou Medical University  Xuzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0214-4771","authenticated-orcid":false,"given":"Aoyang","family":"Yu","sequence":"additional","affiliation":[{"name":"The First Clinical College of Xuzhou Medical University  Xuzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Yu","sequence":"additional","affiliation":[{"name":"The First Clinical College of Xuzhou Medical University  Xuzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Yao","sequence":"additional","affiliation":[{"name":"The First Clinical College of Xuzhou Medical University  Xuzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-454X","authenticated-orcid":false,"given":"Huanxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology Affiliated Hospital of Xuzhou Medical University  Xuzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-9135","authenticated-orcid":false,"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology Affiliated Hospital of Xuzhou Medical University  Xuzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01513"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/life12060812"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001425"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04704-8"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4812637"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.14740\/jh1137"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26774"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.25072"},{"key":"e_1_2_12_14_1","first-page":"295","article-title":"The Amplification of 1q21 Is an Adverse Prognostic Factor in Patients With Multiple Myeloma in a Chinese Population","volume":"9","author":"Yu W.","year":"2016","journal-title":"Oncotargets and Therapy"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0254-0"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1084683"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"issue":"12","key":"e_1_2_12_19_1","first-page":"1186","article-title":"Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2024 Revision)","volume":"63","author":"Chinese Society of Hematology, Chinese Medical Association","year":"2024","journal-title":"Chinese Journal of Internal Medicine"},{"issue":"5","key":"e_1_2_12_20_1","first-page":"480","article-title":"Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2022 Revision)","volume":"61","author":"Chinese Society of Hematology, Chinese Medical Association","year":"2022","journal-title":"Chinese Journal of Internal Medicine"},{"issue":"5","key":"e_1_2_12_21_1","first-page":"341","article-title":"Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2020 Revision)","volume":"59","author":"Chinese Society of Hematology, Chinese Medical Association","year":"2020","journal-title":"Chinese Journal of Internal Medicine"},{"issue":"11","key":"e_1_2_12_22_1","first-page":"866","article-title":"Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2017 Revision)","volume":"56","author":"Chinese Society of Hematology, Chinese Medical Association","year":"2017","journal-title":"Chinese Journal of Internal Medicine"},{"key":"e_1_2_12_23_1","first-page":"251","article-title":"Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD)","volume":"112","author":"Collins G. S.","year":"2015","journal-title":"TRIPOD Statement"},{"issue":"1","key":"e_1_2_12_24_1","first-page":"503","article-title":"The Prognostic Impact of 1q21 Gain\/Amplification in Newly Diagnosed Multiple Myeloma: A Retrospective Study Based on a Single Center in China","volume":"104","author":"Li Y.","year":"2025","journal-title":"Annals of Hematology"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70193"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00348-5"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2018.38.2.160"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3254"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200354"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34641"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26639"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77450-y"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00739.x"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25657"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.11.032"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938550"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506174"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020256"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122003"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009387"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02195-1"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1197340"},{"issue":"1","key":"e_1_2_12_43_1","first-page":"9","article-title":"Impact of Autologous Stem Cell Transplantation (ASCT) on Progression Free Survival (PFS) in Newly Diagnosed Multiple Myeloma Patients (NDMM) With High Risk Cytogenetic Abnormalities","volume":"125","author":"Guman T.","year":"2024","journal-title":"Bratislavsk\u00e9 Lek\u00e1rske Listy"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10907-1"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/15353508241257924"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/15353508241261473"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:52:01Z","timestamp":1791262321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/cam4.72077"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72077","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72077"}}